Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapies by the National Medical Products Administration [1] Group 1: Product Information - SHR-1826 is an antibody-drug conjugate targeting c-Met, designed to specifically bind to tumor cell surface antigens and induce cell death upon internalization [1] - A similar product, ABBV-399 (generic name: telisotuzumab vedotin), received accelerated approval from the FDA in May 2025 for treating adult patients with advanced/metastatic non-squamous non-small cell lung cancer who have previously undergone systemic therapy and exhibit high expression of c-Met protein [1] Group 2: Financial Investment - The cumulative research and development investment related to SHR-1826 has reached approximately 125.5 million yuan [1]

Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of HRS-7535, a novel oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes and weight loss [1] Group 1: Product Development - HRS-7535 is designed to activate GLP-1 receptors, promoting insulin secretion from the pancreas, reducing glucagon secretion, and suppressing gastric emptying [1] - The drug also enhances satiety and suppresses appetite through central mechanisms, leading to reduced energy intake [1] - There are currently no oral small molecule GLP-1 receptor agonists available in the global market [1] Group 2: Financial Investment - The cumulative research and development investment for HRS-7535 has reached approximately 369.4 million yuan [1]

Group 1 - Core viewpoint: Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Suzhou Hengrui Medicine Co., Ltd., has had its injectable SHR-1826 included in the list of breakthrough therapeutic varieties by the National Medical Products Administration [1] - Drug name: Injectable SHR-1826, with acceptance number CXSL2300466, classified as a Class 1 therapeutic biological product [1] - Proposed indication: Monotherapy for locally advanced or metastatic non-squamous non-small cell lung cancer with c-Met overexpression (2-3+, ≥50%) in patients who have failed at least one line of systemic treatment [1] Group 2 - Application date: December 1, 2025, for the registration of SHR-1826 [1] - Reason for inclusion: The application meets the requirements of the "Drug Registration Management Measures" and the announcement regarding the "Breakthrough Therapeutic Drug Review Procedures" [1]

Core Viewpoint - Heng Rui Medicine (01276) has received approval from the National Medical Products Administration for clinical trials of HRS-7535 tablets, aimed at treating hypertension combined with overweight or obesity [1] Group 1: Clinical Trial Approval - The clinical trial approval notice for HRS-7535 was issued on October 27, 2025, confirming that the drug meets the registration requirements [1] - The drug is a novel oral small molecule GLP-1 receptor agonist, which promotes insulin secretion and reduces glucagon secretion while enhancing satiety and suppressing appetite [1] Group 2: Market Potential - HRS-7535 is intended for the treatment of Type 2 Diabetes Mellitus (T2DM) and weight loss, with no oral small molecule GLP-1 receptor agonists currently available in the global market [1] - The total research and development investment for HRS-7535 has reached approximately 369.4 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年1月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-008 ...

江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 孫飄揚先生 中國上海 2026年1月12日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司山东盛迪医 药有 ...

Core Viewpoint - The report highlights the AH premium rates of various stocks, indicating significant discrepancies between their H-shares and A-shares, with some stocks showing extremely high premiums while others exhibit negative premiums. Group 1: Top AH Premium Rates - Northeast Electric (00042) has the highest AH premium rate at 770.97% with a deviation value of -104.86% [1] - Zhejiang Shibao (01057) follows with a premium rate of 432.48% and a deviation value of 91.33% [1] - Nanjing Panda Electronics (00553) ranks third with a premium rate of 288.23% and a deviation value of 78.28% [1] Group 2: Bottom AH Premium Rates - Contemporary Amperex Technology (03750) has the lowest AH premium rate at -12.93% with a deviation value of -2.96% [1] - China Merchants Bank (03968) has a premium rate of -2.18% and a deviation value of -0.26% [1] - Heng Rui Medicine (01276) shows a premium rate of -0.61% with a deviation value of -1.85% [1] Group 3: Top Deviation Values - Zhejiang Shibao (01057) leads in deviation value at 91.33% with a premium rate of 432.48% [2] - Goldwind Technology (02208) has a deviation value of 80.21% with a premium rate of 142.96% [2] - Nanjing Panda Electronics (00553) ranks third in deviation value at 78.28% with a premium rate of 288.23% [2] Group 4: Bottom Deviation Values - Northeast Electric (00042) has the lowest deviation value at -104.86% despite a high premium rate of 770.97% [3] - Morning Paper (01812) shows a deviation value of -45.19% with a premium rate of 201.16% [3] - Nanhua Futures (02691) has a deviation value of -27.51% with a premium rate of 102.69% [3]

格隆汇1月12日丨根据联交所最新权益披露资料显示，2026年1月6日，恒瑞医药(01276.HK)获JPMorgan Chase & Co.以每股均价74.6126港元增持好仓112.78万 股，涉资约8415.02万港元。 | 表格序號 | 大股東/董事/最高行政人員名稱 作出披露的 買入 / 賣出或涉及的股 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的 | | --- | --- | --- | --- | --- | --- | | | | | | | 請參閱上述*註解)有投票權股(日/月/9 | | | | | | | 分自分市 | | CS20260109E00475 | JPMorgan Chase & Co. | 1101(L) | 1,127,828(L | HKD 74.6126 | 19.193.978(L 7.43(L)06/01/2026 | | | | | | | 6,332,713(S) 2.45(S) | | | | | | | 9,502,137(P) 3.68(P) | 增持后，JPMorgan Chase & Co.最新持好仓数目为19,193, ...

Core Viewpoint - JPMorgan has increased its stake in Heng Rui Medicine (01276) by acquiring 1,127,828 shares at a price of HKD 74.6126 per share, totaling approximately HKD 84.15 million, raising its ownership to about 19.19 million shares, which represents a 7.43% stake in the company [2][4]. Summary by Category - **Investment Activity** - JPMorgan's recent purchase of 1,127,828 shares indicates a strategic move to bolster its investment in Heng Rui Medicine [2][4]. - The total investment amount for this transaction is approximately HKD 84.15 million [2][4]. - **Ownership Structure** - Following the acquisition, JPMorgan's total shareholding in Heng Rui Medicine has increased to approximately 19.19 million shares [2][4]. - The new ownership percentage stands at 7.43% of the total shares [2][4].

Group 1 - JPMorgan increased its stake in Heng Rui Medicine (01276) by 1,127,828 shares at a price of HKD 74.6126 per share, totaling approximately HKD 84.15 million [1] - After the increase, JPMorgan's total shareholding in Heng Rui Medicine is approximately 19.194 million shares, representing a holding percentage of 7.43% [1]